Monographie - Ceftaroline fosamil

Ceftaroline fosamil

Structure chimique

Noms commerciaux

Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires

Zinforo

Allemagne, Argentine, Belgique, Chili, Espagne, France, Grande Bretagne, Islande, Malaisie, Mexique, Norvège, Roumanie, Suisse

Bibliographie : Ceftaroline fosamil

	Type	Source
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3520	Laboratoire	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3549	Laboratoire	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Laboratoire	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3812	Revue	Bhattacharya S, Parekh S, Dedhiya M. In-use Stability of Ceftaroline Fosamil in Elastomeric Home Infusion Systems and MINI-BAG Plus Containers. Int J Pharm Compound 2015 ; 19, 5 : 432-436.
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4059	Revue	Madfai F, Zaidi S, Ming L, Wanandy T, Patel R. Physical and chemical stability of ceftaroline in an elastomeric infusion device. EJHP 2017 ; 25, e2
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1: